News Jazz swings further into cancer with Chimerix takeover Jazz has reached an agreement to buy Chimerix for around $935 million, adding a brain cancer drug heading for an FDA approval decision in August.
News Enhertu extends survival in advanced gastric cancer Data from a phase 3 trial of Enhertu in advanced HER2-positive gastric cancer could support wider use as a second-line therapy.
News Takeda scores with polycythemia vera drug in phase 3 trial A phase 3 win suggests Takeda's $300m wager on Protagonist's rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off.
News Owkin launches ATLANTIS patient data mining project Owkin has partnered 20 healthcare institutions on a patient data mining project, ATLANTIS, across oncology, immunology/inflammation, and neurology.
News Regeneron tries again with lymphoma bispecific in US Regeneron has refiled its CD20xCD3 bispecific odronextamab for lymphoma with the FDA, which was rejected last year, but is seeking a narrower label.
News Can Keytruda finally break into early head and neck cancer? The FDA is set to decide on MSD's Keytruda as perioperative treatment of locally advanced head and neck squamous cell carcinoma in June.
News RIF job losses are underway at HHS agencies; reports Reduction in force (RIF) job losses have started in earnest at US federal agencies, including the FDA and CDC, according to media reports.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl